[{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"60bce1a2-b876-426c-a77f-15b4b5b443a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03805919","created_at":"2021-01-18T18:48:39.011Z","updated_at":"2025-02-25T15:34:18.012Z","phase":"","brief_title":"Men at High Genetic Risk for Prostate Cancer","source_id_and_acronym":"NCT03805919","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 01/01/2029","primary_completion_date":" 01/01/2029","study_txt":" Completion: 01/01/2039","study_completion_date":" 01/01/2039","last_update_posted":"2025-02-10"},{"id":"dfa37710-8128-4c60-aefe-7507a106a2e0","acronym":"MK3475-A53","url":"https://clinicaltrials.gov/study/NCT05379972","created_at":"2022-05-18T11:57:02.291Z","updated_at":"2025-02-25T16:17:42.708Z","phase":"Phase 2","brief_title":"Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers","source_id_and_acronym":"NCT05379972 - MK3475-A53","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4","pipe":" | ","alterations":" HRD","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-11-26"},{"id":"0274e43f-cc0c-414e-9481-44dc1368c6ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05515575","created_at":"2022-09-08T14:56:05.365Z","updated_at":"2025-02-25T13:13:08.083Z","phase":"Phase 2","brief_title":"A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA","source_id_and_acronym":"NCT05515575","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 08/23/2022","start_date":" 08/23/2022","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-11-05"},{"id":"1bada8c3-f2f1-4030-ad23-c27e1828e629","acronym":"","url":"https://clinicaltrials.gov/study/NCT04550494","created_at":"2021-01-18T21:45:36.970Z","updated_at":"2024-07-02T16:35:16.133Z","phase":"Phase 2","brief_title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","source_id_and_acronym":"NCT04550494","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation","tags":["BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/26/2021","start_date":" 04/26/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"7235b2f2-0818-493f-a41a-c34684bbba42","acronym":"TRIUMPH","url":"https://clinicaltrials.gov/study/NCT03413995","created_at":"2021-01-18T16:50:34.963Z","updated_at":"2024-07-02T16:35:19.977Z","phase":"Phase 2","brief_title":"Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations","source_id_and_acronym":"NCT03413995 - TRIUMPH","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 11/08/2023","primary_completion_date":" 11/08/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-09"},{"id":"40c5a9dd-b0cf-48c4-bf22-51d4452040b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448718","created_at":"2021-01-18T17:00:17.468Z","updated_at":"2025-02-25T14:58:45.009Z","phase":"Phase 2","brief_title":"Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations","source_id_and_acronym":"NCT03448718","lead_sponsor":"Matthew Galsky","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/17/2018","start_date":" 04/17/2018","primary_txt":" Primary completion: 07/14/2021","primary_completion_date":" 07/14/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2023-11-22"},{"id":"94c45794-3c7a-4a80-9968-91c364190829","acronym":"","url":"https://clinicaltrials.gov/study/NCT03207347","created_at":"2021-01-18T15:48:36.731Z","updated_at":"2025-02-25T13:12:22.396Z","phase":"Phase 2","brief_title":"A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)","source_id_and_acronym":"NCT03207347","lead_sponsor":"University of Florida","biomarkers":" PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4","pipe":" | ","alterations":" BARD1 mutation","tags":["PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2023-09-15"},{"id":"354dc2c5-feeb-41d3-8c1c-e0fb0c8edd00","acronym":"IMPARP-HRD","url":"https://clinicaltrials.gov/study/NCT04985721","created_at":"2021-08-02T14:53:05.727Z","updated_at":"2024-07-02T16:35:53.270Z","phase":"Phase 2","brief_title":"A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects","source_id_and_acronym":"NCT04985721 - IMPARP-HRD","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" BRCA1 • BRCA2 • ATM • HRD • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • FANCL • WRN • FANCI • FANCM • FANCG","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD","tags":["BRCA1 • BRCA2 • ATM • HRD • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • FANCL • WRN • FANCI • FANCM • FANCG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-03-15"},{"id":"45767788-2a80-409b-bc5a-1f4458725f95","acronym":"","url":"https://clinicaltrials.gov/study/NCT02401347","created_at":"2021-01-17T17:55:20.127Z","updated_at":"2024-07-02T16:35:55.106Z","phase":"Phase 2","brief_title":"Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors","source_id_and_acronym":"NCT02401347","lead_sponsor":"Melinda Telli","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • PTEN • HRD • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCL • FANCD2 • FANCE • FANCG • FANCC","pipe":" | ","alterations":" HER-2 negative • HRD","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • PTEN • HRD • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCL • FANCD2 • FANCE • FANCG • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Talzenna (talazoparib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 12/23/2019","primary_completion_date":" 12/23/2019","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-02-21"},{"id":"ee322d77-a5c1-4feb-9b65-e5dafed8ecce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04692662","created_at":"2021-01-19T20:48:57.020Z","updated_at":"2024-07-02T16:36:36.223Z","phase":"Phase 2","brief_title":"Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response","source_id_and_acronym":"NCT04692662","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • CDK12 • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • FANCF mutation • FANCG mutation","tags":["BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • CDK12 • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • FANCF mutation • FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-01-12"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"}]